|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Trovato FM, Tognarelli JM, Crossey MM,
Catalano D, Taylor-Robinson SD and Trovato GM: Challenges of liver
cancer: Future emerging tools in imaging and urinary biomarkers.
World J Hepatol. 7:2664–2675. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al SHARP Investigators Study Group: Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar
|
|
6
|
Qin S, Bai Y, Lim HY, Thongprasert S, Chao
Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y, et al:
Randomized, multi-center, open-label study of oxaliplatin plus
fluorouracil/leucovorin versus doxorubicin as palliative
chemotherapy in patients with advanced hepatocellular carcinoma
from Asia. J Clin Oncol. 31:3501–3508. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zaanan A, Williet N, Hebbar M, Dabakuyo
TS, Fartoux L, Mansourbakht T, Dubreuil O, Rosmorduc O, Cattan S,
Bonnetain F, et al: Gemcitabine plus oxaliplatin in advanced
hepatocellular carcinoma: A large multicenter AGEO study. J
Hepatol. 58:81–88. 2013. View Article : Google Scholar
|
|
8
|
Llovet JM, Villanueva A, Lachenmayer A and
Finn RS: Advances in targeted therapies for hepatocellular
carcinoma in the genomic era. Nat Rev Clin Oncol. 12:408–424. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wörns MA and Galle PR: HCC
therapies-lessons learned. Nat Rev Gastroenterol Hepatol.
11:447–452. 2014. View Article : Google Scholar
|
|
10
|
Wang Z, Li Y, Ahmad A, Azmi AS, Kong D,
Banerjee S and Sarkar FH: Targeting miRNAs involved in cancer stem
cell and EMT regulation: An emerging concept in overcoming drug
resistance. Drug Resist Updat. 13:109–118. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Puisieux A, Brabletz T and Caramel J:
Oncogenic roles of EMT-inducing transcription factors. Nat Cell
Biol. 16:488–494. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mitra A, Mishra L and Li S: EMT, CTCs and
CSCs in tumor relapse and drug-resistance. Oncotarget.
6:10697–10711. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu Q, Wang R, Yang Q, Hou X, Chen S, Hou
Y, Chen C, Yang Y, Miele L, Sarkar FH, et al: Chemoresistance to
gemcitabine in hepatoma cells induces epithelial-mesenchymal
transition and involves activation of PDGF-D pathway. Oncotarget.
4:1999–2009. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang R, Cheng L, Xia J and Wang Z, Wu Q
and Wang Z: Gemcitabine resistance is associated with
epithelial-mesenchymal transition and induction of HIF-1α in
pancreatic cancer cells. Curr Cancer Drug Targets. 14:407–417.
2014. View Article : Google Scholar
|
|
16
|
Güngör C, Zander H, Effenberger KE,
Vashist YK, Kalinina T, Izbicki JR, Yekebas E and Bockhorn M: Notch
signaling activated by replication stress-induced expression of
midkine drives epithelial-mesenchymal transition and
chemoresistance in pancreatic cancer. Cancer Res. 71:5009–5019.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Z, Li Y, Kong D, Banerjee S, Ahmad A,
Azmi AS, Ali S, Abbruzzese JL, Gallick GE and Sarkar FH:
Acquisition of epithelial-mesenchymal transition phenotype of
gemcitabine-resistant pancreatic cancer cells is linked with
activation of the notch signaling pathway. Cancer Res.
69:2400–2407. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rieber M and Strasberg-Rieber M: p53
inactivation decreases dependence on estrogen/ERK signalling for
proliferation but promotes EMT and susceptility to 3-bromopyruvate
in ERα+ breast cancer MCF-7 cells. Biochem Pharmacol.
88:169–177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lin Y, Mallen-St Clair J, Luo J, Sharma S,
Dubinett S and St John M: p53 modulates NF-κB mediated
epithelial-to-mesenchymal transition in head and neck squamous cell
carcinoma. Oral Oncol. 51:921–928. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Alam SK, Yadav VK, Bajaj S, Datta A, Dutta
SK, Bhattacharyya M, Bhattacharya S, Debnath S, Roy S, Boardman LA,
et al: DNA damage-induced ephrin-B2 reverse signaling promotes
chemoresistance and drives EMT in colorectal carcinoma harboring
mutant p53. Cell Death Differ. 23:707–722. 2016. View Article : Google Scholar
|
|
21
|
Wade M, Li YC and Wahl GM: MDM2, MDMX and
p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 13:83–96.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Khoo KH, Verma CS and Lane DP: Drugging
the p53 pathway: Understanding the route to clinical efficacy. Nat
Rev Drug Discov. 13:217–236. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Van Maerken T, Rihani A, Van Goethem A, De
Paepe A, Speleman F and Vandesompele J: Pharmacologic activation of
wild-type p53 by nutlin therapy in childhood cancer. Cancer Lett.
344:157–165. 2014. View Article : Google Scholar
|
|
24
|
Secchiero P, Bosco R, Celeghini C and
Zauli G: Recent advances in the therapeutic perspectives of
Nutlin-3. Curr Pharm Des. 17:569–577. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Barone G, Tweddle DA, Shohet JM, Chesler
L, Moreno L, Pearson AD and Van Maerken T: MDM2-p53 interaction in
paediatric solid tumours: Preclinical rationale, biomarkers and
resistance. Curr Drug Targets. 15:114–123. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zheng T, Yin D, Lu Z, Wang J, Li Y, Chen
X, Liang Y, Song X, Qi S, Sun B, et al: Nutlin-3 overcomes arsenic
trioxide resistance and tumor metastasis mediated by mutant p53 in
hepatocellular carcinoma. Mol Cancer. 13:1332014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Moran DM and Maki CG: Nutlin-3a induces
cytoskeletal rearrangement and inhibits the migration and invasion
capacity of p53 wild-type cancer cells. Mol Cancer Ther. 9:895–905.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang R, Li Y, Hou Y, Yang Q, Chen S, Wang
X, Wang Z, Yang Y, Chen C, Wang Z, et al: The
PDGF-D/miR-106a/Twist1 pathway orchestrates epithelial-mesenchymal
transition in gemcitabine resistance hepatoma cells. Oncotarget.
6:7000–7010. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Saitoh M: Epithelial-mesenchymal
transition is regulated at post-transcriptional levels by
transforming growth factor-β signaling during tumor progression.
Cancer Sci. 106:481–488. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu Y, Fu Y, Zheng L, Lin G, Ma J, Lou J,
Zhu H, He Q and Yang B: Nutlin-3 inhibits epithelial-mesenchymal
transition by interfering with canonical transforming growth
factor-β1-Smad-Snail/Slug axis. Cancer Lett. 342:82–91. 2014.
View Article : Google Scholar
|
|
31
|
Zheng T, Wang J, Song X, Meng X, Pan S,
Jiang H and Liu L: Nutlin-3 cooperates with doxorubicin to induce
apoptosis of human hepatocellular carcinoma cells through p53 or
p73 signaling pathways. J Cancer Res Clin Oncol. 136:1597–1604.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang J, Zheng T, Chen X, Song X, Meng X,
Bhatta N, Pan S, Jiang H and Liu L: MDM2 antagonist can inhibit
tumor growth in hepatocellular carcinoma with different types of
p53 in vitro. J Gastroenterol Hepatol. 26:371–377. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shi X, Liu J, Ren L, Mao N, Tan F, Ding N,
Yang J and Li M: Nutlin-3 downregulates p53 phosphorylation on
serine392 and induces apoptosis in hepatocellular carcinoma cells.
BMB Rep. 47:221–226. 2014. View Article : Google Scholar :
|
|
34
|
Shi XL, Yang J, Mao N, Wu JH, Ren LF, Yang
Y, Yin XL, Wei L, Li MY and Wang BN: Nutlin-3-induced
redistribution of chromatin-bound IFI16 in human hepatocellular
carcinoma cells in vitro is associated with p53 activation. Acta
Pharmacol Sin. 36:252–258. 2015. View Article : Google Scholar :
|
|
35
|
Michaelis M, Rothweiler F, Klassert D, von
Deimling A, Weber K, Fehse B, Kammerer B, Doerr HW and Cinatl J Jr:
Reversal of P-glycoprotein-mediated multidrug resistance by the
murine double minute 2 antagonist nutlin-3. Cancer Res. 69:416–421.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Peirce SK and Findley HW: The MDM2
antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to
doxorubicin via E2F1 and TAp73. Int J Oncol. 34:1395–1402.
2009.PubMed/NCBI
|
|
37
|
Van Maerken T, Ferdinande L, Taildeman J,
Lambertz I, Yigit N, Vercruysse L, Rihani A, Michaelis M, Cinatl J
Jr, Cuvelier CA, et al: Antitumor activity of the selective MDM2
antagonist nutlin-3 against chemoresistant neuroblastoma with
wild-type p53. J Natl Cancer Inst. 101:1562–1574. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Meijer A, Kruyt FA, van der Zee AG,
Hollema H, Le P, ten Hoor KA, Groothuis GM, Quax WJ, de Vries EG
and de Jong S: Nutlin-3 preferentially sensitises wild-type
p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL. Br
J Cancer. 109:2685–2695. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zheng X, Gai X, Han S, Moser CD, Hu C,
Shire AM, Floyd RA and Roberts LR: The human sulfatase 2 inhibitor
2,4-disul-fonylphenyl-tert-butylnitrone (OKN-007) has an antitumor
effect in hepatocellular carcinoma mediated via suppression of
TGFB1/SMAD2 and Hedgehog/GLI1 signaling. Genes Chromosomes Cancer.
52:225–236. 2013. View Article : Google Scholar
|
|
40
|
Wang J, Liu G, Li Q, Wang F, Xie F, Zhai
R, Guo Y, Chen T, Zhang N, Ni W, et al: Mucin1 promotes the
migration and invasion of hepatocellular carcinoma cells via
JNK-mediated phosphorylation of Smad2 at the C-terminal and linker
regions. Oncotarget. 6:19264–19278. 2015. View Article : Google Scholar : PubMed/NCBI
|
